ASAM's Addiction Guidelines Will Now Surface Inside an AI Tool Its Users Already Have Open

The American Society of Addiction Medicine and OpenEvidence announced a partnership on Oct. 28 that puts ASAM's clinical practice guidelines, treatment recommendations and implementation resources inside OpenEvidence's AI platform, where they will surface automatically when a clinician's query touches substance use — alongside the peer-reviewed literature the tool already cites, with links back to the source documents.

The mechanics are unglamorous and that is the point. No new portal, no separate login, no continuing education module. The guidance arrives in the same window a clinician is already looking at while deciding what to prescribe.

What the Partnership Actually Covers

ASAM, founded in 1954, represents more than 8,000 physicians, clinicians and associated professionals. Its National Practice Guideline for opioid use disorder, in its 2020 focused update, revised 35 existing recommendations and added 13 new ones. That document is the closest thing the field has to a consensus standard for medication initiation, dosing and continuation, and it is not widely read outside addiction medicine.

OpenEvidence, founded in 2021 and based in Florida, offers its platform free to verified U.S. clinicians. Its publishing partners include the New England Journal of Medicine, JAMA and the JAMA Network specialty journals, Nature Portfolio, Wiley and Sage. The company closed a $250 million Series D in January 2026, bringing twelve-month fundraising to nearly $700 million and its valuation to $12 billion.

Stephen M. Taylor, ASAM's president, framed the deal as an access question: the society's guidelines, he said, aim to equip clinicians with high-quality, science-based guidance, and the collaboration is meant to make that guidance reachable by all healthcare professionals who may provide care for patients with addiction. Both organizations cited a figure of roughly 44.6 million Americans with a substance use disorder in 2025.

Why Retrieval Is the Whole Point, and Not the Whole Job

Divide one number by the other. Forty-four point six million people with a substance use disorder against 8,000 addiction medicine specialists works out to more than 5,500 patients per specialist, before counting the far larger group with risky use that never meets diagnostic criteria. OpenEvidence made the same argument more bluntly in its own announcement: addiction medicine has clear, specific guidance, and most of the clinicians who need it did not train in it.

That arithmetic is why a guideline's location matters more than its quality. A recommendation that appears when a family physician types a question about buprenorphine induction reaches the person about to write the prescription.

What the announcement does not resolve is the difference between retrieving a recommendation and applying one. An answer engine returns the passage that matches a query. The National Practice Guideline is a set of recommendations with conditions attached — who is eligible, what dose, what monitoring, what to do when the first attempt fails — and a retrieved sentence is a fragment of that structure. Three things are worth watching as the integration goes live: whether each recommendation appears with its strength and evidence rating rather than as bare prose, whether the platform displays the guideline's date so a clinician can tell a 2020 update from a superseded version, and what the interface does when the published literature and the society's guidance point in different directions.

For now the practical effect is narrower than the press release implies and more useful than a new website would have been. A prescriber in a county with no addiction specialist is likelier to encounter ASAM's standard for medication-assisted treatment at the moment it is relevant, rather than never.